Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press50310.17650/1726-9776-2016-12-1-63-68DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыHormonal therapy and chemotherapy in patients with hormone-sensitive prostate cancerГормональная и химиотерапия у больных гормоночувствительным раком предстательной железыGafanovR. A.ГафановР. А.
Russian Federation

86, Profsoyuznaya St., Moscow, 117997

кандидат медицинских наук, старший научный сотрудник научно-исследовательского отдела комплексной диагностики и лечения заболеваний органов мочеполовой системы у взрослых и детей,

117997, Москва, ул. Профсоюзная, 86

docgra@mail.ruFSBI “Russian Scientific Center of Radiology” of Russian Ministry of HealthФГБУ «Российский научный центр рентгенорадиологии» Минздрава России3003201612163682710201502012016https://oncourology.abvpress.ru/oncur/article/view/503

Prostate cancer is the most common men`s cancer in men in developed world and the second cause of death in this population. This review focuses on management of advanced castration resistant prostate cancer (CRPC) has been rapidly changing and is still evolving. In the last years, there has been an increasing knowledge of prostate cancer biology. New therapeutic agents and approaches have been evaluated demonstrating benefits in survival and quality of life in patients with metastatic prostate cancer.

Рак предстательной железы (РПЖ) является наиболее распространенным онкологическим заболеванием у мужчин в развитых странах мира и вторым в ряду причин смертности в этой популяции. Представленный обзор посвящен терапии распространенных форм РПЖ. Подходы к лечению данной нозологии быстро меняются и продолжают развиваться. В последние годы появилось много новой информации о природе РПЖ. Новые терапевтические агенты и подходы продемонстрировали свои преимущества в увеличении общей выживаемости и качества жизни у пациентов с распространенными формами РПЖ.

prostate cancerchemotherapyhormonal therapyрак предстательной железыхимиотерапиягормональная терапия1. Schröder F.H., Hugosson J., Roobol M.J. et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366: 981–90.Schröder F.H., Hugosson J., Roobol M.J. et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366: 981–90.2. Huggins C, Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9–12.Huggins C, Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9–12.3. Denis L.J., Keuppens F., Smith P.H. et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998;33:144–51.Denis L.J., Keuppens F., Smith P.H. et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998;33:144–51.4. Singer E.A., Golijanin D.J., Miyamoto H. et al. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008;9:211–28.Singer E.A., Golijanin D.J., Miyamoto H. et al. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008;9:211–28.5. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34–45.Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34–45.6. Debes J.D., Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488–90.Debes J.D., Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488–90.7. Scher H.I., Buchanan G., Gerald W. et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11:459–76.Scher H.I., Buchanan G., Gerald W. et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11:459–76.8. Gelmann E.P. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001–15.Gelmann E.P. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001–15.9. Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med 2004;22:299–309.Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med 2004;22:299–309.10. Trapman J., Cleutjens K.B. Androgenregulated gene expression in prostate cancer. Semin Cancer Biol 1997;8:29–36.Trapman J., Cleutjens K.B. Androgenregulated gene expression in prostate cancer. Semin Cancer Biol 1997;8:29–36.11. Chen Y., Sawyers C.L., Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440–8.Chen Y., Sawyers C.L., Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440–8.12. Edwards J., Krishna N.S., Grigor K.M. et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552–6.Edwards J., Krishna N.S., Grigor K.M. et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552–6.13. Mostaghel E.A., Page S.T., Lin D.W. et al. Intraprostatic androgens and androgenregulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67:5033–41.Mostaghel E.A., Page S.T., Lin D.W. et al. Intraprostatic androgens and androgenregulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67:5033–41.14. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.15. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.16. Pound C.R., Partin A.W., Epstein J.I. et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395–406.Pound C.R., Partin A.W., Epstein J.I. et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395–406.17. D’Amico A.V., Whittington R., Malkowicz S.B. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.D’Amico A.V., Whittington R., Malkowicz S.B. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.18. D’Amico A.V., Cote K., Loffredo M. et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:4567–73.D’Amico A.V., Cote K., Loffredo M. et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:4567–73.19. Bastian P.J., Boorjian S.A., Bossi A. et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012;61:1096–106.Bastian P.J., Boorjian S.A., Bossi A. et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012;61:1096–106.20. Kattan M.W., Eastham J.A., Stapleton A.M. et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766–71.Kattan M.W., Eastham J.A., Stapleton A.M. et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766–71.21. Eastham J.A., Kelly W.K., Grossfeld G.D. et al. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62:55–62.Eastham J.A., Kelly W.K., Grossfeld G.D. et al. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62:55–62.22. Fizazi K., Lesaunier F., Delva R. et al. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer 2012;48:209–17.Fizazi K., Lesaunier F., Delva R. et al. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer 2012;48:209–17.23. Sandler H.M, Chen Hu, Rosenthal S.A. et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol 2015;33(Suppl), abstr LBA5002.Sandler H.M, Chen Hu, Rosenthal S.A. et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol 2015;33(Suppl), abstr LBA5002.24. Schweizer M.T., Huang P., Kattan M.W. et al. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer 2013;119:3610–8.Schweizer M.T., Huang P., Kattan M.W. et al. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer 2013;119:3610–8.25. Attard G., Sydes M.R., Mason M.D. et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol 2014;66:799–802.Attard G., Sydes M.R., Mason M.D. et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol 2014;66:799–802.26. James N.D., Sydes M.R., Mason M.D. et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 2012;13:549–58.James N.D., Sydes M.R., Mason M.D. et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 2012;13:549–58.27. James N.D., Sydes M.R., Mason M.D. et al. Docetaxel and/or zoledronic acid for hormonenaïve prostate cancer: First overall survival results from STAMPEDE. J Clin Oncol 2015;(suppl) abstr 5001.James N.D., Sydes M.R., Mason M.D. et al. Docetaxel and/or zoledronic acid for hormonenaïve prostate cancer: First overall survival results from STAMPEDE. J Clin Oncol 2015;(suppl) abstr 5001.28. James N.D., Spears M.R., Clarke N.W. et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015;67:1028–38.James N.D., Spears M.R., Clarke N.W. et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015;67:1028–38.29. Sweeney C., Chen Y.H., Carducci M.A. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 2014;32:abstr LBA2.Sweeney C., Chen Y.H., Carducci M.A. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 2014;32:abstr LBA2.30. Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149–58.Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149–58.31. Fontana D., Bertetto O., Fasolis G. et al. Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 1998;84:39–44.Fontana D., Bertetto O., Fasolis G. et al. Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 1998;84:39–44.32. Murphy G.P., Beckley S., Brady M.F. et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983;51:1264–72.Murphy G.P., Beckley S., Brady M.F. et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983;51:1264–72.33. Murphy G.P., Huben R.P., Priore R. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 1986;28:36–40.Murphy G.P., Huben R.P., Priore R. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 1986;28:36–40.34. Osborne C.K., Blumenstein B., Crawford E.D. et al. Combined versus sequential chemoendocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol 1990;8:1675–82.Osborne C.K., Blumenstein B., Crawford E.D. et al. Combined versus sequential chemoendocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol 1990;8:1675–82.35. Pummer K., Lehnert M., Stettner H. et al. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997;32:81–5.Pummer K., Lehnert M., Stettner H. et al. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997;32:81–5.36. Janknegt R.A., Boon T.A., van de Beek C. et al. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology 1997;49:411–20.Janknegt R.A., Boon T.A., van de Beek C. et al. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology 1997;49:411–20.37. Millikan R.E., Wen S., Pagliaro L.C. et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008;26:5936–42.Millikan R.E., Wen S., Pagliaro L.C. et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008;26:5936–42.38. Wang J., Halford S., Rigg A. et al. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000;86:675–80.Wang J., Halford S., Rigg A. et al. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000;86:675–80.39. Gravis G., Boher J.M., Joly F. et al. Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormonenaïve metastatic prostate cancer (PCa): Longterm analysis of the GETUG-AFU 15 phase III trial. J Clin Oncol 2015;abstr 140.Gravis G., Boher J.M., Joly F. et al. Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormonenaïve metastatic prostate cancer (PCa): Longterm analysis of the GETUG-AFU 15 phase III trial. J Clin Oncol 2015;abstr 140.40. Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8):737–46.Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8):737–46.41. Eisenberger M.A., Blumenstein B.A., Crawford E.D. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036–42.Eisenberger M.A., Blumenstein B.A., Crawford E.D. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036–42.42. Recine F., Sternberg C.N. Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Transl Androl Urol 2015;4(3):355–64. doi: 10.3978/j.issn.2223-4683.2015.04.11.Recine F., Sternberg C.N. Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Transl Androl Urol 2015;4(3):355–64. doi: 10.3978/j.issn.2223-4683.2015.04.11.